1. Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Ther Adv Gastroenterol. 2023 Mar;16:17562848231163410. https://doi.org/10.1177/17562848231163410. [DOI] [PubMed]

2. Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, et al. AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury. Hepatology. 2023 Mar;77(3):1036-65. https://doi.org/10.1002/hep.32689. [DOI] [PubMed]

3. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol. 2021 May;116(5):878-98. https://doi.org/10.14309/ajg.0000000000001259. [DOI] [PubMed]

4. Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, et al. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants (Basel). 2021 Mar;10(3):390. https://doi.org/10.3390/antiox10030390. [DOI] [PubMed]

5. Walayat S, Shoaib H, Asghar M, Kim M, Dhillon S. Role of N-acetylcysteine in non-acetaminophen-related acute liver failure: an updated meta-analysis and systematic review. Ann Gastroenterol. 2021;34(2):235-40. https://doi.org/10.20524/aog.2021.0571. [DOI] [PubMed]

6. Ahmed T, Ahmad J. Recent advances in the diagnosis of drug-induced liver injury. World J Hepatol. 2024 Feb;16(2):186-92. https://doi.org/10.4254/wjh.v16.i2.186. [DOI] [PubMed]

7. Vajdi M, Adeli S, Karimi A, Asghariazar V, Moini Jazani A, Nasimidoost Azgomi R. The Impact of Silymarin on Inflammation and Oxidative Stress: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Clin Pract. 2025; 3985207. https://doi.org/10.1155/ijcp/3985207. [Link] [DOI]

8. Sayyad M, Sutar AD, Shivhare K, Shukla R, Flora SJS. Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. Front Pharmacol. 2025 Nov;16:1711653. https://doi.org/10.3389/fphar.2025.1711653. [DOI] [PubMed]

9. Gillessen A, Schmidt HH. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther. 2020 Apr;37(4):1279-1301. https://doi.org/10.1007/s12325-020-01251-y. [DOI] [PubMed]

10. Jaffar HM, Al-Asmari F, Khan FA, Rahim MA, Zongo E. Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases-A comprehensive narrative review. Food Sci Nutr. 2024 Feb;12(5):3097-3111. https://doi.org/10.1002/fsn3.4010. [DOI] [PubMed]

11. Calderon Martinez E, Herrera D, Mogan S, Hameed Z, Jangda AA, Khan TJ, et al. Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review. Cureus. 2023 Oct;15(10):e47608. https://doi.org/10.7759/cureus.47608. [DOI] [PubMed]

12. Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1235-38. https://doi.org/10.1097/meg.0b013e32833aa11b. [DOI] [PubMed]

13. Moosa MS, Maartens G, Gunter H, Allie S, Chughlay MF, Setshedi M, et al. A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. Clin Infect Dis. 2021 Nov;73(9):e3377-e3383. https://doi.org/10.1093/cid/ciaa1255. [DOI] [PubMed]

14. Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010 Apr;50(4):434-49. https://doi.org/10.1177/0091270009347475. [DOI] [PubMed]

15. Li M, Luo Q, Tao Y, Sun X, Liu C. Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review. Front Pharmacol. 2022 Jan;12:806249. https://doi.org/10.3389/fphar.2021.806249. [DOI] [PubMed]

16. Gillessen A, Angelico F, Chen J, Lu L, Lucena MI, Fu Q, et al. Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations. Gastro Hep Adv. 2022 May;1(5):882-93. https://doi.org/10.1016/j.gastha.2022.05.006. [DOI] [PubMed]

17. Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, et al. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Ann Med. 2022 Dec;54(1):1548-60. https://doi.org/10.1080/07853890.2022.2069854. [DOI] [PubMed]

18. Li C, Yang X, Quan Y, Wu A, Wang Y. Network meta-analysis of different liver protective drugs in the treatment of drug-induced liver injury. Medicine (Baltimore). 2023 Dec;102(50):e36538. https://doi.org/10.1097/md.0000000000036538. [DOI] [PubMed]

19. Sanabria-Cabrera J, Tabbai S, Niu H, Alvarez-Alvarez I, Licata A, Björnsson E, et al. N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review. Front Pharmacol. 2022 May;13:876868. https://doi.org/10.3389/fphar.2022.876868. [DOI] [PubMed]

20. Jerome RN, Zahn LA, Abner JJ, Joly MM, Shirey-Rice JK, Wallis RS, et al. Repurposing N-acetylcysteine for management of non-acetaminophen induced acute liver failure: an evidence scan from a global health perspective. Transl Gastroenterol Hepatol. 2024 Jan;9:2. https://doi.org/10.21037/tgh-23-40. [DOI] [PubMed]

21. Tighe SP, Akhtar D, Iqbal U, Ahmed A. Chronic Liver Disease and Silymarin: A Biochemical and Clinical Review. J Clin Transl Hepatol. 2020 Dec;8(4):454-58. https://doi.org/10.14218/jcth.2020.00012. [DOI] [PubMed]

22. Faryadi S, Sheikhahmadi A, Farhadi A, Nourbakhsh H. Evaluating the therapeutic effect of different forms of silymarin on liver status and expression of some genes involved in fat metabolism, antioxidants and anti-inflammatory in older laying hens. Vet Med Sci. 2024 Nov;10(6):e70025. https://doi.org/10.1002/vms3.70025. [DOI] [PubMed]

23. Dos Santos AC, França TCS, Venzon L, Polli V, Polleti G, Trembulak E, et al. Are silymarin and N-acetylcysteine able to prevent liver damage mediated by multiple factors? Findings against ethanol plus LPS-induced liver injury in mice. J Biochem Mol Toxicol. 2024 Jan;38(1):e23560. https://doi.org/10.1002/jbt.23560. [DOI] [PubMed]

24. Ntamo Y, Ziqubu K, Chellan N, Nkambule BB, Nyambuya TM, Mazibuko-Mbeje SE, et al. Drug-Induced Liver Injury: Clinical Evidence of N-Acetyl Cysteine Protective Effects. Oxid Med Cell Longev. 2021 Dec;2021:3320325. https://doi.org/10.1155/2021/3320325. [DOI] [PubMed]

25. Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017 Jun;66(6):1154-64. https://doi.org/10.1136/gutjnl-2016-313369. [DOI] [PubMed]

26. Shahsavari K, Ardekani SS, Ardekani MRS, Esfahani MM, Kazemizadeh H, Jamialahmadi T, et al. Are alterations needed in Silybum marianum (Silymarin) administration practices? A novel outlook and meta-analysis on randomized trials targeting liver injury. BMC Complement Med Ther. 2025 Apr;25(1):134. https://doi.org/10.1186/s12906-025-04886-y. [DOI] [PubMed]

27. Teschke R. Treatment of Drug-Induced Liver Injury. Biomedicines. 2022 Dec;11(1):15. https://doi.org/10.3390/biomedicines11010015. [DOI] [PubMed]

28. Ngetich DK, Korir S, Okoth M. Restorative effects of Silymarin milk thistle on the liver following paracetamol-induced hepatotoxicity in adult albino rats. Anatomy Journal of Africa. 2023;12(3):2489-97. https://dx.doi.org/10.4314/aja.v12i3.5. [Link] [DOI]